Daylife Select
A point & click tool to create dynamic content portals. Learn More »
NEW YORK - A brain infection linked to Biogen Idec Inc. and Elan Corp.’s Tysabri is more likely to occur the longer patients use the multiple sclerosis drug, new prescribing information says. Full Article at Boston Globe
Related Articles
-
ELAN HAS updated the label on its breakthrough multiple sclerosis (MS) drug Tysabri to reflect the increased risk of patients contracting a serious brain disease if they are on the drug for more than two years. Full Article at Irish Times
-
Elan and Biogen Idec's multiple sclerosis drug Tysabri has been linked to four deaths by the European Medicines Agency. Full Article at Irish Independent
-
PATIENTS WITH Crohn’s disease are less likely to be hospitalised if they are using Tysabri, according to figures produced by the drug’s developers, Irish biotech group Elan and US-based Biogen Idec. Full Article at Irish Times
-
Elan Corporation, plc (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) today announced data showing that treatment with TYSABRI® (natalizumab) significantly reduced the rate of hospitalization compared with placebo in patients with moderate–to–severe Crohn’s... Full Article at News-Medical.net
